These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 26894509)
1. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells. Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509 [TBL] [Abstract][Full Text] [Related]
2. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298 [TBL] [Abstract][Full Text] [Related]
3. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Lin TH; Izumi K; Lee SO; Lin WJ; Yeh S; Chang C Cell Death Dis; 2013 Aug; 4(8):e764. PubMed ID: 23928703 [TBL] [Abstract][Full Text] [Related]
4. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals. Wen S; Tian J; Niu Y; Li L; Yeh S; Chang C Cancer Lett; 2016 Jul; 376(2):377-86. PubMed ID: 27045473 [TBL] [Abstract][Full Text] [Related]
5. ASC-J9 Lin W; Luo J; Sun Y; Lin C; Li G; Niu Y; Chang C Cancer Lett; 2018 Jul; 425():21-30. PubMed ID: 29425687 [TBL] [Abstract][Full Text] [Related]
6. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429 [TBL] [Abstract][Full Text] [Related]
7. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L. Wang R; Lin W; Lin C; Li L; Sun Y; Chang C Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475 [TBL] [Abstract][Full Text] [Related]
8. Androgen receptor (AR) degradation enhancer ASC-J9 Cheng MA; Chou FJ; Wang K; Yang R; Ding J; Zhang Q; Li G; Yeh S; Xu D; Chang C Cancer Lett; 2018 Mar; 417():182-191. PubMed ID: 29203251 [TBL] [Abstract][Full Text] [Related]
9. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814 [TBL] [Abstract][Full Text] [Related]
10. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling. Tian H; Chou FJ; Tian J; Zhang Y; You B; Huang CP; Yeh S; Niu Y; Chang C J Exp Clin Cancer Res; 2021 Jan; 40(1):3. PubMed ID: 33390173 [TBL] [Abstract][Full Text] [Related]
11. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276 [TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression. Luo J; Tian J; Chou F; Lin C; Xing EZ; Zuo L; Niu Y; Yeh S; Chang C Cancer Lett; 2019 Mar; 444():35-44. PubMed ID: 30248372 [TBL] [Abstract][Full Text] [Related]
13. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression. Chou FJ; Chen Y; Chen D; Niu Y; Li G; Keng P; Yeh S; Chang C EBioMedicine; 2019 Feb; 40():504-516. PubMed ID: 30692044 [TBL] [Abstract][Full Text] [Related]
14. Osajin displays potential antiprostate cancer efficacy via impairment of fatty acid synthase and androgen receptor expression. Huang SY; Huang GJ; Hsieh PF; Wu HC; Huang WC Prostate; 2019 Sep; 79(13):1543-1552. PubMed ID: 31299104 [TBL] [Abstract][Full Text] [Related]
15. Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals. Dang Q; Li L; Xie H; He D; Chen J; Song W; Chang LS; Chang HC; Yeh S; Chang C Mol Oncol; 2015 Aug; 9(7):1241-51. PubMed ID: 25817444 [TBL] [Abstract][Full Text] [Related]
16. Androgen Receptor Regulation of Local Growth Hormone in Prostate Cancer Cells. Recouvreux MV; Wu JB; Gao AC; Zonis S; Chesnokova V; Bhowmick N; Chung LW; Melmed S Endocrinology; 2017 Jul; 158(7):2255-2268. PubMed ID: 28444169 [TBL] [Abstract][Full Text] [Related]
17. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036 [TBL] [Abstract][Full Text] [Related]
18. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells. Lee SO; Ma Z; Yeh CR; Luo J; Lin TH; Lai KP; Yamashita S; Liang L; Tian J; Li L; Jiang Q; Huang CK; Niu Y; Yeh S; Chang C J Mol Cell Biol; 2013 Feb; 5(1):14-26. PubMed ID: 22831834 [TBL] [Abstract][Full Text] [Related]
19. Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model. Tyan YS; Lee YP; Chuang HY; Wang WH; Hwang JJ Biosci Rep; 2021 May; 41(5):. PubMed ID: 33974005 [TBL] [Abstract][Full Text] [Related]
20. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]